Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Surgeries & Interventions June 9, 2025

Contrast Use During PCI on the Decline June 9, 2025

New ACC registry data suggests interventional cardiologists are using less contrast for PCI procedures in the cath lab which helps reduce post-PCI acute kidney injury risks, but a deeper look tells us there’s still room for improvement. Searching for cath lab trends, researchers examined 3.12M unique PCI procedures performed by 3.6k physicians from 2018 to […]

Cardiology Pharmaceuticals June 5, 2025

Regeneron & Hansoh’s GLP-1 Deal June 5, 2025

Just a few weeks after the full results of SURMOUNT-5 crowned Eli Lilly’s GLP-1/GIP tirzepatide king of the GLP-1s, Regeneron announced it will pay Hansoh Pharma $80M upfront and up to $1.93B in milestone payments for its Phase 3-stage GLP-1/GIP drug, HS-20094. It’s the early testing edge that has Regeneron excited about Hansoh’s HS-20094, since […]

More Stories

Cardiology Pharmaceuticals June 2, 2025

Deeper Answers from the ABYSS Trial June 2, 2025

Diving deeper into the ABYSS trial, a new sub-analysis suggests that patients with MI and preserved LVEF who stop taking their beta-blockers experience significant rises in heart rate and BP, potentially increasing their risk of adverse events.  Now ABYSS’ new sub-analysis gives insights as to why beta-blockers help reduce adverse outcomes post-MI by examining the […]

Cardiology Business May 29, 2025

Boston Scientific Bows Out on TAVR May 29, 2025

Marking its departure from the TAVR market, Boston Scientific officially discontinued sales of its Acurate neo2 and Acurate Prime TAVR systems and will no longer seek approval from the FDA or other regulatory agencies. While there’s no one reason to blame for Boston’s decision, it’s likely the recent three way clinical comparison trial presented at […]

Surgeries & Interventions May 22, 2025

Navitor Versus Sapien 3 Ultra: Different in the Details May 22, 2025

One year data from the NAVULTRA study published in JACC suggests that Edwards’ Sapien 3 Ultra and Abbott’s Navitor intra-annular TAVR valves have similar short-term clinical outcomes, with a few key differences. The NAVULTRA study explored data from 4k TAVR patients who received either Navitor or Sapien 3 Ultra and found that all-cause mortality was […]

Cardiology Pharmaceuticals May 19, 2025

Wegovy Rapidly Lowers MACE Risk May 19, 2025

Getting us closer to understanding GLP-1s’ heart benefits, a post hoc analysis of the SELECT trial suggests that Novo Nordisk’s Wegovy (semaglutide) significantly reduces a patient’s MACE risk in just three months of treatment.  Researchers analyzed the SELECT trial data by looking at CV events in the first three to six months following semaglutide treatment […]

Cardiology Pharmaceuticals May 15, 2025

Tirzepatide Beats Semaglutide in Weight Loss May 15, 2025

Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic). Weighing the weight loss benefits of each drug, SURMOUNT-5’s researchers randomized 751 obese patients without T2D to receive either tirzepatide (10mg/15mg) […]

Cardiology Testing May 12, 2025

Predicting ASCVD With Calprotectin May 12, 2025

Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early. So how does calprotectin predict ASCVD? To answer this, researchers measured calprotectin levels in plasma collected from 2.4k participants during Phase 2 of the Dallas Heart Study […]

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!